NVDA
NVIDIA
-- 134.250 AVGO
Broadcom
-- 224.800 TSLA
Tesla
-- 436.230 AMD
Advanced Micro Devices
-- 126.910 PLTR
Palantir
-- 76.070 
NEWS
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-month progression-free survival of 94.6%. The study enrolled 39 patients with a median age of 68 years.
In the second trial, ZYNLONTA as monotherapy for relapsed/refractory marginal zone lymphoma demonstrated a 91% overall response rate and 70% complete response rate in 23 patients. The median duration of complete response was 11.5 months, with the longest follow-up at 27 months.
In the second trial, ZYNLONTA as monotherapy for relapsed/refractory marginal zone lymphoma demonstrated a 91% overall response rate and 70% complete response rate in 23 patients. The median duration of complete response was 11.5 months, with the longest follow-up at 27 months.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment